RE: Divi payouts. Scores on the doors25 Mar 2020 21:30
The drug, which significantly helps to cure the coronavirus intensive care situation, has been developed by Faron Pharmaceuticals Oy, Finland. Traumakine was originally developed for severe acute respiratory distress syndrome.
There is still no marketing authorization for the medicine, but given the crisis situation caused by coronavirus, there is evidence that there is sufficient evidence of its efficacy and safety in relation to its benefits.
We require that Fimea, the Center for Pharmaceutical Safety and Development, authorize the use of the drug as soon as possible for those who wish to receive Traumakine for intensive care. The medicine is already manufactured and stored in Finland in sufficient quantities for treatment. This drug has the potential to save hundreds if not thousands of lives in Finland.
The address will be handed over to Fimea on Friday 27.3.2020.